한글목차

COVID 19 전용 항바이러스제 시장 규모는 최근 급성장하고 있습니다. 2025년 152억 3,000만 달러에서 2026년에는 178억 3,000만 달러에 이르고, CAGR 17.1%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장은 코로나19의 급속한 확산, 긴급사용허가 취득, 기존 항바이러스제에 대한 의존도, 세계 생산능력의 한계, 높은 입원율 등이 요인으로 작용한 것으로 보입니다.

COVID 19 전용 항바이러스제 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 331억 7,000만 달러에 이르고, CAGR은 16.8%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 차세대 항바이러스제 개발, 민관 협력 강화, 예방적 치료의 보급 확대, 병용요법 확대, 개인 맞춤형 의료 접근법 통합 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 코로나19 항바이러스제 개발 투자 증가, 경구용 항바이러스제 채택 확대, 단클론 항체 치료제의 성장, 병원 및 소매 유통 채널 확대, 입원 환자 및 고위험군 환자 대상 표적치료에 대한 집중 등이 있습니다.

향후 몇 년 동안 코로나19 확진자 증가로 인해 코로나19에 대한 특정 항바이러스제 시장이 확대될 것으로 예측됩니다. 코로나19 확진자란 코로나19의 원인인 SARS-CoV-2 바이러스에 감염된 것으로 확인된 개인을 말합니다. 코로나19 확진자 증가는 주로 더 높은 감염력과 백신 접종이나 과거 감염으로 얻은 면역력을 부분적으로 회피하는 능력을 보이는 새로운 변종 바이러스의 출현에 기인합니다. 코로나19에 대한 특정 항바이러스제는 질병의 중증도를 낮추고 회복 기간을 단축하여 질병 관리를 지원함으로써 환자의 예후를 개선하고 코로나19와 관련된 전반적인 의료 부담을 줄일 수 있습니다. 예를 들어, 2025년 5월 세계보건기구(WHO)의 발표에 따르면, 스위스에 본부를 둔 이 국제 공중보건기구에 따르면, 동지중해 지역의 검사 양성률은 2025년 초 4%에서 17%로 급증하여 2024년 같은 기간의 수준을 넘어섰다고 합니다. 따라서, 코로나19 확진자 증가가 코로나19에 대한 특정 항바이러스제 시장의 성장을 주도하고 있습니다.

코로나19 감염증을 위한 특정 항바이러스제 시장에서 사업을 전개하는 주요 기업들은 치료 접근성을 높이고 임상 효과를 높이기 위해 경구용 항바이러스 요법 등 혁신적인 치료법 개발에 집중하고 있습니다. 경구용 항바이러스 치료는 바이러스 복제를 억제하여 작용하는 경구용 약물로, 코로나19 치료에 편리하고 효과적인 접근법을 제공합니다. 예를 들어, 2024년 3월 일본 제약회사 시오노기제약은 항바이러스제 엔시트레빌의 제품명 '조코바'를 출시하고 후생노동성(MHLW)으로부터 정식 승인을 받았습니다. 이 치료법은 노출 후 예방적 투여로도 효과적이며, 노출자의 코로나19 발병 위험을 크게 낮추고 증상 지속 기간을 단축하는 동시에 양호한 안전성 프로파일을 유지합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Specific antiviral drugs for COVID-19 are medications developed to directly target and suppress the replication or activity of the SARS-CoV-2 virus, which is responsible for COVID-19. These drugs help lessen the severity and shorten the duration of infection by disrupting key viral processes such as entry into host cells, replication, or viral assembly.

The main forms of specific antiviral drugs for COVID-19 include tablets and injectable formulations. Tablets are solid dosage forms containing an exact amount of active pharmaceutical ingredients along with excipients, compressed into small, typically flat or oval shapes. These antiviral medications are used for hospitalized patients, non-hospitalized patients, and for preventive treatment. The drug classes include nucleoside analogues, protease inhibitors, RNA polymerase inhibitors, entry inhibitors, and monoclonal antibodies. They are administered through various routes such as oral, intravenous, subcutaneous, and inhalation, and are distributed through channels including hospital pharmacies, retail pharmacies, and other distribution outlets.

Tariffs have affected the specific antiviral drugs for COVID-19 market by increasing the cost of imported active pharmaceutical ingredients (APIs) and raw materials used in tablet and injection formulations. Segments such as nucleoside analogues and monoclonal antibodies are particularly impacted, with regions like Asia-Pacific, including China and India, facing significant import duties. While this raises production costs and can delay supply, tariffs have also encouraged local API production, investment in domestic manufacturing, and innovation in drug formulation strategies.

The specific antiviral drugs for covid 19 market research report is one of a series of new reports from The Business Research Company that provides specific antiviral drugs for covid 19 market statistics, including specific antiviral drugs for covid 19 industry global market size, regional shares, competitors with a specific antiviral drugs for covid 19 market share, detailed specific antiviral drugs for covid 19 market segments, market trends and opportunities, and any further data you may need to thrive in the specific antiviral drugs for covid 19 industry. This specific antiviral drugs for covid 19 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The specific antiviral drugs for covid 19 market size has grown rapidly in recent years. It will grow from $15.23 billion in 2025 to $17.83 billion in 2026 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to rapid spread of covid-19, emergency use authorizations, reliance on traditional antiviral drug classes, limited global production capacity, high hospitalization rates.

The specific antiviral drugs for covid 19 market size is expected to see rapid growth in the next few years. It will grow to $33.17 billion in 2030 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to development of next-generation antiviral drugs, increased public-private partnerships, rising preventive treatment adoption, expansion of combination therapies, integration of personalized medicine approaches. Major trends in the forecast period include rising investment in covid-19 antiviral drug development, increasing adoption of oral antiviral tablets, growth in monoclonal antibody therapies, expansion of hospital and retail distribution channels, focus on targeted treatment for hospitalized and high-risk patients.

The growing number of COVID-19 cases is anticipated to drive the expansion of the specific antiviral drugs for the COVID-19 market in the coming years. COVID-19 cases refer to individuals who have tested positive for infection with the SARS-CoV-2 virus, the causative agent of COVID-19. The increase in COVID-19 cases is largely attributed to the emergence of new viral variants that demonstrate higher transmissibility and partial ability to evade immunity gained from vaccination or prior infection. Specific antiviral drugs for COVID-19 support disease management by lowering illness severity and shortening recovery time, thereby improving patient outcomes and reducing the overall healthcare burden associated with COVID-19. For example, in May 2025, according to the World Health Organization, a Switzerland-based global public health agency, the test positivity rate in the Eastern Mediterranean region rose sharply from 4% to 17% in early 2025, exceeding levels recorded during the same period in 2024. Therefore, the increasing number of COVID-19 cases is driving the growth of the specific antiviral drugs for the COVID-19 market.

Major companies operating in the specific antiviral drugs for the COVID-19 market are concentrating on the development of innovative treatment options, such as oral antiviral therapies, to improve treatment accessibility and clinical effectiveness. Oral antiviral therapies are medications administered by mouth that work by inhibiting viral replication, offering a convenient and effective approach to treating COVID-19. For instance, in March 2024, Shionogi & Co., a Japan-based pharmaceutical company, launched Xocova and received full standard approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its antiviral drug ensitrelvir. The therapy also provides post-exposure prophylaxis by significantly lowering the risk of symptomatic COVID-19 among exposed individuals and reducing symptom duration while maintaining a favorable safety profile.

In July 2024, GSK plc, a UK-based pharmaceutical company, partnered with CureVac to jointly develop and commercialize next-generation mRNA vaccines targeting COVID-19 and influenza. This collaboration aims to advance innovative mRNA-based vaccines to enhance global public health outcomes. CureVac N.V. is a Germany-based biotechnology company specializing in the development of messenger RNA (mRNA)-based therapies.

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the specific antiviral drugs for covid 19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The specific antiviral drugs for COVID-19 market consists of sales of host-directed antivirals, immunomodulators, fusion inhibitors, helicase inhibitors, and tmprss2 inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Specific Antiviral Drugs For COVID 19 Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses specific antiviral drugs for covid 19 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for specific antiviral drugs for covid 19 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The specific antiviral drugs for covid 19 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Tablet; Injection
• 2) By Indication: Hospitalized Patients; Non-Hospitalized Patients; Preventive Treatment
• 3) By Drug Class: Nucleoside Analogues; Protease Inhibitors; Ribonucleic Acid Polymerase Inhibitors; Entry Inhibitors; Monoclonal Antibodies
• 4) By Route Of Administration: Oral; Intravenous; Subcutaneous; Inhalation
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Tablet: Oral Antiviral Tablets; Combination Antiviral Tablets; Extended-Release Tablets
• 2) By Injection: Intravenous (IV) Antiviral Injections; Intramuscular (IM) Antiviral Injections; Subcutaneous Antiviral Injections
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Gilead Sciences Inc.; Shionogi & Co. Ltd.; Cipla Limited; Hetero Drugs Limited; Roche Holding AG; Johnson & Johnson; Novartis AG; GSK plc; Eli Lilly and Company; Regeneron Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Beximco Pharmaceuticals Limited; Atea Pharmaceuticals Inc.; Enanta Pharmaceuticals Inc.; RedHill Biopharma Ltd.; Synairgen plc; Dr. Reddy's Laboratories Ltd.; Aurobindo Pharma Ltd.; Lupin Limited; Natco Pharma Ltd.; Zydus Lifesciences Ltd.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Hikma Pharmaceuticals PLC; Alkem Laboratories Ltd.; Torrent Pharmaceuticals Ltd.; Apotex Inc.; Mylan N.V.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Specific Antiviral Drugs For COVID 19 Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Specific Antiviral Drugs For COVID 19 Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Specific Antiviral Drugs For COVID 19 Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Specific Antiviral Drugs For COVID 19 Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Investment In COVID-19 Antiviral Drug Development
  • 4.2.2 Increasing Adoption Of Oral Antiviral Tablets
  • 4.2.3 Growth In Monoclonal Antibody Therapies
  • 4.2.4 Expansion Of Hospital And Retail Distribution Channels
  • 4.2.5 Focus On Targeted Treatment For Hospitalized And High-Risk Patients

5. Specific Antiviral Drugs For COVID 19 Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Retail Pharmacies
• 5.3 Healthcare Clinics
• 5.4 Government Health Programs
• 5.5 Contract Research Organizations (CROs)

6. Specific Antiviral Drugs For COVID 19 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Specific Antiviral Drugs For COVID 19 Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Specific Antiviral Drugs For COVID 19 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Specific Antiviral Drugs For COVID 19 Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Specific Antiviral Drugs For COVID 19 Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Specific Antiviral Drugs For COVID 19 Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Specific Antiviral Drugs For COVID 19 Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Specific Antiviral Drugs For COVID 19 Market Segmentation

• 9.1. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tablet, Injection
• 9.2. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment
• 9.3. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies
• 9.4. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Intravenous, Subcutaneous, Inhalation
• 9.5. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
• 9.6. Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets
• 9.7. Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

10. Specific Antiviral Drugs For COVID 19 Market Regional And Country Analysis

• 10.1. Global Specific Antiviral Drugs For COVID 19 Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Specific Antiviral Drugs For COVID 19 Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market

• 11.1. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Specific Antiviral Drugs For COVID 19 Market

• 12.1. China Specific Antiviral Drugs For COVID 19 Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Specific Antiviral Drugs For COVID 19 Market

• 13.1. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Specific Antiviral Drugs For COVID 19 Market

• 14.1. Japan Specific Antiviral Drugs For COVID 19 Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Specific Antiviral Drugs For COVID 19 Market

• 15.1. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Specific Antiviral Drugs For COVID 19 Market

• 16.1. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Specific Antiviral Drugs For COVID 19 Market

• 17.1. South Korea Specific Antiviral Drugs For COVID 19 Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Specific Antiviral Drugs For COVID 19 Market

• 18.1. Taiwan Specific Antiviral Drugs For COVID 19 Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Specific Antiviral Drugs For COVID 19 Market

• 19.1. South East Asia Specific Antiviral Drugs For COVID 19 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Specific Antiviral Drugs For COVID 19 Market

• 20.1. Western Europe Specific Antiviral Drugs For COVID 19 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Specific Antiviral Drugs For COVID 19 Market

• 21.1. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Specific Antiviral Drugs For COVID 19 Market

• 22.1. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Specific Antiviral Drugs For COVID 19 Market

• 23.1. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Specific Antiviral Drugs For COVID 19 Market

• 24.1. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Specific Antiviral Drugs For COVID 19 Market

• 25.1. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Specific Antiviral Drugs For COVID 19 Market

• 26.1. Eastern Europe Specific Antiviral Drugs For COVID 19 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Specific Antiviral Drugs For COVID 19 Market

• 27.1. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Specific Antiviral Drugs For COVID 19 Market

• 28.1. North America Specific Antiviral Drugs For COVID 19 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Specific Antiviral Drugs For COVID 19 Market

• 29.1. USA Specific Antiviral Drugs For COVID 19 Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Specific Antiviral Drugs For COVID 19 Market

• 30.1. Canada Specific Antiviral Drugs For COVID 19 Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Specific Antiviral Drugs For COVID 19 Market

• 31.1. South America Specific Antiviral Drugs For COVID 19 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Specific Antiviral Drugs For COVID 19 Market

• 32.1. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Specific Antiviral Drugs For COVID 19 Market

• 33.1. Middle East Specific Antiviral Drugs For COVID 19 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Specific Antiviral Drugs For COVID 19 Market

• 34.1. Africa Specific Antiviral Drugs For COVID 19 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Specific Antiviral Drugs For COVID 19 Market Regulatory and Investment Landscape

36. Specific Antiviral Drugs For COVID 19 Market Competitive Landscape And Company Profiles

• 36.1. Specific Antiviral Drugs For COVID 19 Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Specific Antiviral Drugs For COVID 19 Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Specific Antiviral Drugs For COVID 19 Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Shionogi & Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis

37. Specific Antiviral Drugs For COVID 19 Market Other Major And Innovative Companies

• Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd.

38. Global Specific Antiviral Drugs For COVID 19 Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Specific Antiviral Drugs For COVID 19 Market

40. Specific Antiviral Drugs For COVID 19 Market High Potential Countries, Segments and Strategies

• 40.1 Specific Antiviral Drugs For COVID 19 Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Specific Antiviral Drugs For COVID 19 Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Specific Antiviral Drugs For COVID 19 Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer